Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion

The identification of driver mutations in epidermal growth factor receptor, anaplastic lymphoma kinase, the BRAF and ROS1 genes and subsequent successful clinical development of kinase inhibitors not only significantly improves clinical outcomes but also facilitates the discovery of other novel driv...

Descripción completa

Detalles Bibliográficos
Autor principal: Chu, Quincy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984433/
https://www.ncbi.nlm.nih.gov/pubmed/32047535
http://dx.doi.org/10.1177/1758835919895756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984433/
https://www.ncbi.nlm.nih.gov/pubmed/32047535
http://dx.doi.org/10.1177/1758835919895756

Ejemplares similares